24.01.2023 13:23:33
|
Johnson & Johnson Q4 Profit Down 26%, But Adj. EPS Tops Estimates
(RTTNews) - Healthcare company Johnson & Johnson (JNJ) on Tuesday reported that profit for fourth quarter declined 25.9 percent from last year, reflecting a sales decline and higher provisions for income taxes.
Adjusted earnings per share topped analysts' expectations, while quarterly revenues missed it by a whisker. The company also initiated operational earnings forecast for the full-year 2023, above estimates.
For the fourth quarter, net earnings declined about 25 percent to $3.52 billion or $1.33 per share from $4.74 billion or $1.77 per share in the prior-year quarter.
Excluding items, adjusted net earnings for the quarter were $6.22 billion or $2.35 per share, compared to $5.68 billion or $2.13 per share in the year-ago quarter.
On average, 14 analysts polled by Thomson Reuters expected the company to report earnings of $2.23 per share for the quarter. Analysts' estimates typically exclude special items.
Sales for the quarter decreased 4.4 percent to $23.71 billion from $24.80 billion in the same quarter last year, primarily hurt by unfavorable foreign exchange and reduced COVID-19 vaccine sales. Analysts expected revenues of $23.94 billion for the quarter.
Operational sales, excluding COVID-19 Vaccine, grew 4.6 percent. Operational sales edged up 0.9 percent and adjusted operational sales edged up 0.8 percent.
Region-wise, US sales grew 2.9 percent to $12.52 billion, while international sales declined 11.5 percent to $11.19 billion from last year.
Consumer Health worldwide sales edged up 1 percent to $3.77 billion, while pharmaceutical worldwide sales declined 7.4 percent to $13.16 billion and medical devices worldwide sales decreased 1.2 percent to $6.78 billion from last year. Looking ahead to fiscal 2023, the company now projects adjusted earnings in a range of $10.45 to $10.65 per share and adjusted operational earnings in a range of $10.40 to $10.60 per share.
Additionally, the company now projects reported sales and operational sales between $96.9 billion and $97.9 billion, with adjusted operational sales growth of 3.5 to 4.5 percent. The Street is looking for earnings of $10.33 per share on a revenue growth of 2.9 percent to $97.84 billion for the year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
17.12.24 |
NYSE-Handel Dow Jones am Dienstagnachmittag mit Abgaben (finanzen.at) | |
17.12.24 |
Dow Jones-Handel aktuell: Dow Jones fällt (finanzen.at) | |
16.12.24 |
Schwacher Handel in New York: Dow Jones schlussendlich in Rot (finanzen.at) | |
11.12.24 |
Angespannte Stimmung in New York: Dow Jones beendet die Mittwochssitzung im Minus (finanzen.at) | |
11.12.24 |
Schwache Performance in New York: Dow Jones notiert nachmittags im Minus (finanzen.at) | |
11.12.24 |
Zuversicht in New York: Dow Jones mit Kursplus (finanzen.at) | |
11.12.24 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel hätten Anleger mit einem Investment in Johnson Johnson von vor 10 Jahren verdient (finanzen.at) | |
11.12.24 |
Schwacher Wochentag in New York: Dow Jones zum Start des Mittwochshandels in der Verlustzone (finanzen.at) |